Cargando…

Potential Therapeutic Benefit of NAD(+) Supplementation for Glaucoma and Age-Related Macular Degeneration

Glaucoma and age-related macular degeneration are leading causes of irreversible blindness worldwide with significant health and societal burdens. To date, no clinical cures are available and treatments target only the manageable symptoms and risk factors (but do not remediate the underlying patholo...

Descripción completa

Detalles Bibliográficos
Autores principales: Cimaglia, Gloria, Votruba, Marcela, Morgan, James E., André, Helder, Williams, Pete A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551676/
https://www.ncbi.nlm.nih.gov/pubmed/32961812
http://dx.doi.org/10.3390/nu12092871
_version_ 1783593235098107904
author Cimaglia, Gloria
Votruba, Marcela
Morgan, James E.
André, Helder
Williams, Pete A.
author_facet Cimaglia, Gloria
Votruba, Marcela
Morgan, James E.
André, Helder
Williams, Pete A.
author_sort Cimaglia, Gloria
collection PubMed
description Glaucoma and age-related macular degeneration are leading causes of irreversible blindness worldwide with significant health and societal burdens. To date, no clinical cures are available and treatments target only the manageable symptoms and risk factors (but do not remediate the underlying pathology of the disease). Both diseases are neurodegenerative in their pathology of the retina and as such many of the events that trigger cell dysfunction, degeneration, and eventual loss are due to mitochondrial dysfunction, inflammation, and oxidative stress. Here, we critically review how a decreased bioavailability of nicotinamide adenine dinucleotide (NAD; a crucial metabolite in healthy and disease states) may underpin many of these aberrant mechanisms. We propose how exogenous sources of NAD may become a therapeutic standard for the treatment of these conditions.
format Online
Article
Text
id pubmed-7551676
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75516762020-10-14 Potential Therapeutic Benefit of NAD(+) Supplementation for Glaucoma and Age-Related Macular Degeneration Cimaglia, Gloria Votruba, Marcela Morgan, James E. André, Helder Williams, Pete A. Nutrients Review Glaucoma and age-related macular degeneration are leading causes of irreversible blindness worldwide with significant health and societal burdens. To date, no clinical cures are available and treatments target only the manageable symptoms and risk factors (but do not remediate the underlying pathology of the disease). Both diseases are neurodegenerative in their pathology of the retina and as such many of the events that trigger cell dysfunction, degeneration, and eventual loss are due to mitochondrial dysfunction, inflammation, and oxidative stress. Here, we critically review how a decreased bioavailability of nicotinamide adenine dinucleotide (NAD; a crucial metabolite in healthy and disease states) may underpin many of these aberrant mechanisms. We propose how exogenous sources of NAD may become a therapeutic standard for the treatment of these conditions. MDPI 2020-09-19 /pmc/articles/PMC7551676/ /pubmed/32961812 http://dx.doi.org/10.3390/nu12092871 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Cimaglia, Gloria
Votruba, Marcela
Morgan, James E.
André, Helder
Williams, Pete A.
Potential Therapeutic Benefit of NAD(+) Supplementation for Glaucoma and Age-Related Macular Degeneration
title Potential Therapeutic Benefit of NAD(+) Supplementation for Glaucoma and Age-Related Macular Degeneration
title_full Potential Therapeutic Benefit of NAD(+) Supplementation for Glaucoma and Age-Related Macular Degeneration
title_fullStr Potential Therapeutic Benefit of NAD(+) Supplementation for Glaucoma and Age-Related Macular Degeneration
title_full_unstemmed Potential Therapeutic Benefit of NAD(+) Supplementation for Glaucoma and Age-Related Macular Degeneration
title_short Potential Therapeutic Benefit of NAD(+) Supplementation for Glaucoma and Age-Related Macular Degeneration
title_sort potential therapeutic benefit of nad(+) supplementation for glaucoma and age-related macular degeneration
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551676/
https://www.ncbi.nlm.nih.gov/pubmed/32961812
http://dx.doi.org/10.3390/nu12092871
work_keys_str_mv AT cimagliagloria potentialtherapeuticbenefitofnadsupplementationforglaucomaandagerelatedmaculardegeneration
AT votrubamarcela potentialtherapeuticbenefitofnadsupplementationforglaucomaandagerelatedmaculardegeneration
AT morganjamese potentialtherapeuticbenefitofnadsupplementationforglaucomaandagerelatedmaculardegeneration
AT andrehelder potentialtherapeuticbenefitofnadsupplementationforglaucomaandagerelatedmaculardegeneration
AT williamspetea potentialtherapeuticbenefitofnadsupplementationforglaucomaandagerelatedmaculardegeneration